GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating
As of 9 December 2025, GSK plc (LSE: GSK; NYSE: GSK) stock is trading close to its 52‑week highs on both sides of the Atlantic, after a year in which the UK pharma group has upgraded guidance, accelerated buybacks and largely defused one of the biggest litigation overhangs in the sector. On the NYSE, GSK ADRs change hands around $48–49, very near their 52‑week high of $49.31, and up roughly 37% over the past year, versus about 14% for the S&P 500 over the same period. Yahoo Finance+1 On the London Stock Exchange, GSK trades around £18.0, also just below